Author: Boyle A, Marra F, Ritchie T, Campbell J, Hunter C, Peters E, Barclay S

Theme: Clinical Research Year: 2019

Background: Data on treatment outcomes with Glecaprevir/Pibrentasvir (G/P) amongst people who use drugs are lacking, with few enrolled in registration trials. We sought to evaluate the impact of baseline drug use on SVR rates in a real world cohort. Methods: Patients commencing G/P prior to 01/05/2018 were identified from the Scottish HCV database. For patients on ORT, review of drug service notes identified (where available) self reported intravenous drug use (IVDU), and non-IVDU in the 3/12 pre-treatment. Anonymous linkage with the needle exchange database (NEO) identified Injecting equipment provision (IEP) uptake in the same 3/12. Results: 354 people commenced treatment (250 (70.6%) male, mean age 45.2 (±9.3), 33 (9.3%) with cirrhosis, 187 (52.8% GT3)). Self reported drug use, NEO registration and IEP uptake are summarised below. IEP uptake was highest amongst those in specialist care, though 1:4 in non specialist care (shared care with general practice) accessed IEP. Premature discontinuation was infrequent irrespective of baseline drug use (4 (3.0%) with vs 2 (2.6%) without). Intention to treat (ITT) and modified ITT (mITT) rates were high for the cohort (91.5 and 97.5%) respectively. Non SVR was predominantly due to non attendance (15), relapse (6) and death (4). ITT and mITT rates were similar according to presence/absence of baseline drug use (90.4% vs 89.6% (p 0.86), 96.8% vs 97.2% (p 0.87)). Addictions Care Self reported IVDU (%) Self reported Non-IVDU (%) Any evidence DU (%) NEO registered (%) Needle transactions (%) Specialist care 16/160 10.0) 79/160 (49.4) 107/160(66.9) 97 (67.4) 46 (31.9) Shared care 1/37 (2.7) 18 /36 (50.0) 26/37 (70.3) 36 (50.0) 16 (25.8) Not in care n/a n/a n/a 35 (23.6) 9 (6.1) Total 17 (8.6) 97 (49.5) 133 (67.5) 168 (47.5) 71 (20.0) Conclusion: We demonstrate that SVR rates in a real world cohort treated with G/P are high, irrespective of drug use. Disclosure of Interest Statement: This work was sponsored by Abbvie. Dr S Barclay has received speakers fees, advisory board fees and grants from Abbvie and Gilead. Miss F Marra has received speakers fees, advisory board fees and grants from Abbvie, Gilead and Merck. Miss Boyle has received speakers fees and grants from Abbvie and Gilead.

Download abstract Download presentation Watch video